» Articles » PMID: 23143695

The Cardiovascular System in Growth Hormone Excess and Growth Hormone Deficiency

Overview
Publisher Springer
Specialty Endocrinology
Date 2012 Nov 13
PMID 23143695
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

The clinical conditions associated with GH excess and GH deficiency (GHD) are known to be associated with an increased risk for the cardiovascular morbidity and mortality, suggesting that either an excess or a deficiency in GH and/or IGF-I is deleterious for cardiovascular system. In patients with acromegaly, chronic GH and IGF-I excess commonly causes a specific cardiomyopathy characterized by a concentric cardiac hypertrophy associated with diastolic dysfunction and, in later stages, with systolic dysfunction ending in heart failure if GH/IGF-I excess is not controlled. Abnormalities of cardiac rhythm and anomalies of cardiac valves can also occur. Moreover, the increased prevalence of cardiovascular risk factors, such as hypertension, diabetes mellitus, and insulin resistance, as well as dyslipidemia, confer an increased risk for vascular atherosclerosis. Successful control of the disease is accompanied by a decrease of the cardiac mass and improvement of cardiac function and an improvement in cardiovascular risk factors. In patients with hypopituitarism, GHD has been considered the under- lying factor of the increased mortality when appropriate standard replacement of the pituitary hormones deficiencies is given. Either childhood-onset or adulthood-onset GHD are characterized by a cluster of abnormalities associated with an increased cardiovascular risk, including altered body composition, unfavorable lipid profile, insulin resistance, endothelial dysfunction and vascular atherosclerosis, a decrease in cardiac mass together with an impairment of systolic function mainly after exercise. Treatment with recombinant GH in patients with GHD is followed by an improvement of the cardiovascular risk factors and an increase in cardiac mass together with an improvement in cardiac performance. In conclusion, acromegaly and GHD are associated with an increased risk for cardiovascular morbidity and mortality, but the control of GH/IGF-I secretion reverses cardiovascular abnormalities and restores the normal life expectancy.

Citing Articles

Diastolic Dysfunction with Normal Ejection Fraction and Reduced Heart Rate in Mice Expressing Human Growth Hormone and Displaying Signs of Growth Hormone Insufficiency.

Jin Y, Xiang B, Dolinsky V, Kardami E, Cattini P Int J Mol Sci. 2025; 26(1.

PMID: 39796124 PMC: 11719473. DOI: 10.3390/ijms26010269.


Electrocardiographic ventricular arrhythmia parameters during diagnosis and after the treatment of acromegaly: A case-control study.

Tekin Z, Pamukcu H, Kayihan S, Ucan B, Bostan H, Gul U Heliyon. 2024; 10(19):e38033.

PMID: 39398067 PMC: 11471207. DOI: 10.1016/j.heliyon.2024.e38033.


Cardiovascular risk and glucocorticoids: a Dutch National Registry of growth hormone treatment in adults with growth hormone deficiency analysis.

Slagboom T, van Bunderen C, van der Lely A, Drent M Pituitary. 2024; 27(5):590-604.

PMID: 39215905 PMC: 11513701. DOI: 10.1007/s11102-024-01448-2.


The Double-Edged Sword of Total Antioxidant Capacity: Clinical Significance and Personal Experience.

Silvestrini A, Mancini A Antioxidants (Basel). 2024; 13(8).

PMID: 39199179 PMC: 11351343. DOI: 10.3390/antiox13080933.


Cardiovascular Effects of Excess Growth Hormone: How Real is the Threat?.

Rivera F, Talino M, Ansay M, Mangubat G, Mahilum M, Menghrajani R Rev Cardiovasc Med. 2024; 24(4):95.

PMID: 39076279 PMC: 11273026. DOI: 10.31083/j.rcm2404095.


References
1.
Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson B . Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh). 1993; 129(3):195-200. DOI: 10.1530/acta.0.1290195. View

2.
Andreassen M, Faber J, Kjaer A, Petersen C, Kristensen L . Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary. 2010; 14(1):1-10. DOI: 10.1007/s11102-010-0250-7. View

3.
Colao A, Baldelli R, Marzullo P, Ferretti E, Ferone D, Gargiulo P . Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. J Clin Endocrinol Metab. 2000; 85(1):193-9. DOI: 10.1210/jcem.85.1.6318. View

4.
Cenci M, Conceicao F, Soares D, Spina L, Brasil R, Lobo P . Impact of 5 years of growth hormone replacement therapy on cardiovascular risk factors in growth hormone-deficient adults. Metabolism. 2007; 57(1):121-9. DOI: 10.1016/j.metabol.2007.08.015. View

5.
Smith W, Nair R, Adamson D, Kearney M, Ball S, Balmforth A . Somatostatin receptor subtype expression in the human heart: differential expression by myocytes and fibroblasts. J Endocrinol. 2006; 187(3):379-86. DOI: 10.1677/joe.1.06082. View